Cargando…

New agents in relapsed/refractory Hodgkin's lymphoma()

Detalles Bibliográficos
Autores principales:	Biasoli, Irene, Spector, Nelson
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Sociedade Brasileira de Hematologia e Hemoterapia 2017
Materias:	Scientific Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5568577/ https://www.ncbi.nlm.nih.gov/pubmed/28830595 http://dx.doi.org/10.1016/j.bjhh.2017.05.003

Ejemplares similares

Monoclonal B-cell lymphocytosis()
por: Biasoli, Irene, et al.
Publicado: (2015)

Fertility in female survivors of Hodgkin's lymphoma
por: Biasoli, Irene, et al.
Publicado: (2012)

Hodgkin's lymphoma in developing countries: can we go further?()
por: Gaiolla, Rafael Dezen
Publicado: (2017)

Relapsed/Refractory Hodgkin Lymphoma
por: Sheikh, Semira, et al.
Publicado: (2018)

Novel Agents For Relapsed and Refractory Classical Hodgkin Lymphoma: A Review
por: Zhang, Yujie, et al.
Publicado: (2022)

Comment on “Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study.”
por: Picardi, Marco, et al.
Publicado: (2021)

Brentuximab vedotin for relapsed or refractory Hodgkin’s lymphoma
por: Chen, Runzhe, et al.
Publicado: (2015)

Hematopoietic stem cell transplantation for Hodgkin's disease
por: Patah, Poliana, et al.
Publicado: (2011)

Integrating Novel Agents in Relapsed or Refractory Hodgkin Lymphoma: Highlights From SOHO 2020
Publicado: (2021)

Therapeutic Updates for Relapsed and Refractory Classical Hodgkin Lymphoma
por: Voorhees, Timothy J, et al.
Publicado: (2020)

Checkpoint Inhibitors in Relapsed/Refractory Classical Hodgkin Lymphoma
por: Tarekegn, Kidist, et al.
Publicado: (2021)

Everolimus as a single agent in refractory or relapsed Hodgkin's lymphoma: the Brazilian Named Patient Program Experience
por: Rocha, Talita Máira Bueno da Silveira da, et al.
Publicado: (2017)

Immunotoxin – a new treatment option in patients with relapsed and refractory Hodgkin lymphoma
por: Novakovic, Barbara Jezersek
Publicado: (2015)

Hodgkin Lymphoma: Comments on ESMO Clinical Practice Guidelines
por: Aurer, Igor, et al.
Publicado: (2020)

Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma. The Hellenic experience
por: Angelopoulou, Maria K., et al.
Publicado: (2017)

ESHAP salvage therapy for relapsed or refractory non-Hodgkin's lymphoma.
por: Choi, Chul Won, et al.
Publicado: (2002)

Role of brentuximab vedotin in the treatment of relapsed or refractory Hodgkin lymphoma
por: Siddiqi, Tanya, et al.
Publicado: (2014)

Clinical Options in Relapsed or Refractory Hodgkin Lymphoma: An Updated Review
por: Fedele, Roberta, et al.
Publicado: (2015)

Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey
por: Salihoglu, A., et al.
Publicado: (2014)

Dual Immunotherapy Adds Value in Relapsed/Refractory Hodgkin Lymphoma
por: Hallam, Simon
Publicado: (2018)

Zanubrutinib monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma
por: Phillips, Tycel, et al.
Publicado: (2022)

Diffuse large B cell gastric lymphoma a rare disease: the effort to obtain scientific data in a multicenter, multinational retrospective trial()
por: Hamerschlak, Nelson
Publicado: (2016)

Importance of baseline PET/CT imaging on radiation field design and relapse rates in patients with Hodgkin lymphoma
por: Figura, Nick, et al.
Publicado: (2017)

A novel strategy for the screening for platelet refractoriness: prospects and limitations
por: Arruda, Valder R.
Publicado: (2013)

Lymphoma: streamlining follow ups
por: Hallack Neto, Abrahão Elias
Publicado: (2013)

Plasma cells in classical Hodgkin lymphoma: a new player in the microenvironment?
por: Visser, Lydia
Publicado: (2018)

Commentary on the WHO classification of tumors of lymphoid tissues (2008): “Gray zone” lymphomas overlapping with Burkitt lymphoma or classical Hodgkin lymphoma
por: Hasserjian, Robert P., et al.
Publicado: (2009)

Emerging Pharmacotherapy for Relapsed or Refractory Hodgkin’s Lymphoma: Focus on Brentuximab Vedotin
por: Furtado, Michelle, et al.
Publicado: (2012)

Genomic Instability: The Driving Force behind Refractory/Relapsing Hodgkin’s Lymphoma
por: Knecht, Hans, et al.
Publicado: (2013)

Role of Hematopoietic Stem Cell Transplantation in Relapsed/Refractory Hodgkin Lymphoma
por: Carella, Angelo Michele
Publicado: (2012)

Update on Salvage Options in Relapsed/Refractory Hodgkin Lymphoma after Autotransplant
por: Iqbal, Nida, et al.
Publicado: (2014)

Gemcitabine and oxaliplatinum: an effective regimen in patients with refractory and relapsing Hodgkin lymphoma
por: Gutierrez, Antonio, et al.
Publicado: (2014)

Phase 2 study of everolimus for relapsed or refractory classical Hodgkin lymphoma
por: Johnston, Patrick B., et al.
Publicado: (2018)

The Emerging Role of CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma
por: Meier, Jeremy A., et al.
Publicado: (2022)

PB2064: RELAPSED/REFRACTORY HODGKIN LYMPHOMA PATIENTS TREATED WITH RADIOTHERAPY
por: Kallel, F., et al.
Publicado: (2022)

Checkpoint inhibitor immunotherapy during pregnancy for relapsed–refractory Hodgkin lymphoma
por: Evens, Andrew M., et al.
Publicado: (2022)

Filling the Gap: The Immune Therapeutic Armamentarium for Relapsed/Refractory Hodgkin Lymphoma
por: Hazane Leroyer, Esther, et al.
Publicado: (2022)

Optimizing Treatment for Relapsed/Refractory Classic Hodgkin Lymphoma in the Era of Immunotherapy
por: Randall, Michael P., et al.
Publicado: (2023)

Efficacy of Brentuximab Vedotin and Nivolumab in Refractory or Relapsed Hodgkin Lymphoma: A Systematic Review
por: Macapagal, Sharina C, et al.
Publicado: (2022)

Treatment outcomes in classic Hodgkin lymphoma: 5‐year update from the Brazilian Hodgkin Lymphoma Registry
por: Biasoli, Irene, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_rjesnc6njarf175ijdthe39ai6